APRACLONIDINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Apraclonidine Hydrochloride, and when can generic versions of Apraclonidine Hydrochloride launch?
Apraclonidine Hydrochloride is a drug marketed by Rising and is included in one NDA.
The generic ingredient in APRACLONIDINE HYDROCHLORIDE is apraclonidine hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apraclonidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Apraclonidine Hydrochloride
A generic version of APRACLONIDINE HYDROCHLORIDE was approved as apraclonidine hydrochloride by RISING on March 12th, 2009.
Summary for APRACLONIDINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 3 |
Patent Applications: | 381 |
DailyMed Link: | APRACLONIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for APRACLONIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Alabama at Birmingham | Phase 4 |
American University of Beirut Medical Center | Phase 2 |
Walter Reed Army Medical Center | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for APRACLONIDINE HYDROCHLORIDE
US Patents and Regulatory Information for APRACLONIDINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rising | APRACLONIDINE HYDROCHLORIDE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 077764-001 | Mar 12, 2009 | AT | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |